Related Experiment Videos
Parenteral chloroquine for treating falciparum malaria
The Journal of Infectious Diseases
|February 1, 1987
Summary
Parenteral chloroquine for severe malaria can be safely administered with adjusted dosing. Frequent, smaller doses or continuous intravenous infusion minimize toxicity risks associated with high peak concentrations.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Limited consensus exists on optimal chloroquine administration for severe malaria.
- Parenteral chloroquine, despite safety concerns, is frequently used in clinical practice.
Purpose of the Study:
- To investigate the acute disposition and toxicity of various parenteral chloroquine administration routes (intravenous, intramuscular, subcutaneous) compared to oral administration in severe falciparum malaria patients.
Main Methods:
- Studied 60 adult Zambian patients with falciparum malaria.
- Analyzed plasma concentration profiles and pharmacokinetic data for intravenous, intramuscular, subcutaneous, and oral chloroquine.
- Assessed acute toxicity related to drug disposition.
Main Results:
- Parenteral chloroquine administration resulted in significant fluctuations between peak and trough plasma concentrations.
- Intramuscular and subcutaneous absorption were rapid, achieving peak concentrations five times higher than oral doses.
- Acute toxicity appears linked to transiently high blood concentrations due to incomplete distribution.
Conclusions:
- Parenteral chloroquine can be administered more safely by using smaller, more frequent doses.
- Continuous intravenous infusion is a potential alternative for safe administration.
- Optimizing dosing strategies can mitigate risks associated with parenteral chloroquine in severe malaria.